Sunho Biologics Suspends Trading Pending 2025 Annual Results

Bulletin Express04-01

Sunho Biologics, Inc. announced that trading in its shares on the Stock Exchange of Hong Kong has been halted at the company’s request from 9:00 a.m. on 1 April 2026.

The suspension follows earlier notices dated 27 March 2026 and 30 March 2026, which disclosed a delay in publishing the firm’s audited 2025 annual results and the postponement of the corresponding board meeting.

Trading will remain suspended until Sunho Biologics releases the outstanding 2025 annual results announcement.

As of the suspension date, the board comprises Executive Directors Mr. Zhang Feng (Chairman) and Ms. Jiang Xiaoling; Non-Executive Director Mr. Fan Rongkui; and Independent Non-Executive Directors Mr. Chan Heung Wing Anthony, Ms. Feng Lan and Mr. Shi Luwen.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment